Allarity Therapeutics (ALLR): Price-to-Revenue Coefficient

Corporate company logo of Allarity (ALLR)

Geopolitical instability and sanctions are disrupting biomaterial supplies, slowing global oncology research. The current P/S valuation clearly confirms the asset's volatility, where 44.20 records a new level. Transparent management seeks to adapt Allarity Therapeutics (ALLR) to exchange standards, yet a critical dependence on a single therapy selection platform creates significant binary risks for investors.

ALLR: Allarity Therapeutics Price-to-Revenue Ratio 07/25/2022 - 11/16/2026

Analytical breakdowns for Allarity Therapeutics Inc. (ALLR)

- stock value and consensus price forecast:
Fundamental company analysis:ALLR - Allarity Therapeutics
Manufactured products of Allarity Therapeutics, Inc.

Allarity Therapeutics (ALLR) operates within an autonomous R&D cycle, where business value depends on regulatory successes in oncotherapy. The price-to-sales trend reflects the degree of speculative overvaluation of shares relative to current operating revenues. This multiple compares market capitalization with revenue volume, allowing for the identification of asset overheating or the presence of a margin of safety. Analyzing the curve helps investors assess capital stability in the absence of steady sales.